Treats major depressive disorder (MDD). ANDA 208228, held by Apotex. Vilazodone Hydrochloride.
As of Nov 16, 2026, ANDA 208228 (Vilazodone Hydrochloride), held by Apotex, was first approved by FDA on Jul 7, 2023, with 2 approved supplements and 0 published complete response letters.
Vilazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults ].
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 7, 2023 | Original application | Approved | None posted |
| Vilazodone Hydrochloride10MG · tablet;oral | Vilazodone Hydrochloride | Rx |
| Vilazodone Hydrochloride20MG · tablet;oral | Vilazodone Hydrochloride | Rx |
| Vilazodone Hydrochloride40MG · tablet;oral | Vilazodone Hydrochloride | Rx |
| Jan 14, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 3, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 7, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters